|Bid||259.50 x 300|
|Ask||261.00 x 100|
|Day's Range||259.76 - 273.25|
|52 Week Range||244.28 - 370.57|
|PE Ratio (TTM)||21.82|
|Earnings Date||Apr 23, 2018 - Apr 27, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||378.90|
As discussed earlier, Pfizer’s (PFE) revenue rose ~1% to $13.7 billion during 4Q17 driven by increased sales of its Innovative Health products. It reflects revenues for both Pfizer’s Innovative Health and Essential Health segments in 4Q17. Pfizer reported a fall of ~4% in its US sales in 4Q17, while its sales outside US markets reported a 5% revenue rise in the quarter.
Biogen will present data from its portfolio of investigational therapies for people with neurodegenerative diseases at the Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting in Torino, Italy .
This June, some 16,000 people will descend on the Boston Convention & Exhibition Center for the BIO International Convention, a closely-watched annual gathering that gives biotech companies another platform to pitch themselves to investors and each other. The Biotechnology Innovation Organization, the lobbying group that organizes the event, announced on Wednesday that the Motown star and former lead singer of The Supremes will perform a concert on the third night of the convention. Described on BIO’s website as a “networking event,” the concert will give attendees a chance to hear some of her biggest hits while they sip drinks, exchange business cards and discuss the latest in biotech news.
Biogen Inc. announced today that it will present at the Advances in Alzheimer’s and Parkinson’s Therapies, an AAT-AD/PD Focus Meeting. A plenary session titled “The Importance of Early Identification and Treatment of Alzheimer’s Disease” will be webcast live on Thursday, March 15, 2018 at 8:00 a.m.
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Biogen has agreed to acquire a schizophrenia drug candidate from New York-based pharmaceutical giant Pfizer Inc. The purchase allows Cambridge, Massachusetts-based Biogen (BIIB) to develop a new treatment for cognitive impairment. “When cognition is impaired, you lose the ability to make sense of the world," said Michael Ehlers, executive vice president, Research & Development at Biogen.
Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, tumbled alongside the broader market in February. In fact, IBB’s February loss surpassed those ...
Biogen Inc said on Monday it would buy Pfizer Inc's experimental treatment for a symptom associated with schizophrenia in a deal that could near $600 million and mark its foray into the emerging market for neuropsychiatry. Biogen said it plans to start mid-stage tests on the drug, which is being developed to treat cognitive impairment associated with schizophrenia, in the latter half of the year once the deal closes as expected in the second quarter. A majority of the 20 million people living with schizophrenia worldwide experience some degree of cognitive impairment, Biogen said.
Biogen Inc. said Monday it reached a deal to buy a phase-2b-trial-ready schizophrenia treatment, PF-04958242, from Pfizer Inc. for up to $590 million. The deal includes an upfront payment of $75 million ...
Biogen Inc. announced today an agreement to acquire from Pfizer Inc. PF-04958242, a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia .
Biogen today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA® among pre-symptomatic infants with spinal muscular atrophy .
Healthcare sector has proven itself to be one of the most resilient sectors of the US economy. Since healthcare cannot be outsourced and represents an expense that people usually cut on last during economic downturns, investing in healthcare stocks is a good way to recession-proof your portfolio. Moreover, the sector itself is comprised of many […]
How far off is Biogen Inc (NASDAQ:BIIB) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...